Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).
Arun Azad(Peter MacCallum Cancer Centre), Kim N.(Asian Institute of Technology), Renee Lester(Baker Hughes (Canada)), Raya Leibowitz‐Amit(The University of Texas MD Anderson Cancer Center), Anthony M. Joshua(St Vincent's Hospital Sydney), Bernhard J. Eigl(BC Cancer Agency), Daniel Yick Chin Heng(University of Calgary)
Cited by 7
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k